NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model

Area of Science:

• Neuroscience
• Pharmacology
• Movement Disorders

Background:

• Parkinson's disease (PD) involves dopaminergic cell loss, leading to N-methyl-d-aspartate receptor (NMDAR) dysregulation.
• This dysregulation impacts the cortico-striato-pallidal-thalmo-cortical network and cognitive functions.
• Targeting NMDARs is a potential strategy for treating cognitive impairment in PD.

Purpose of the Study:

• To evaluate the efficacy of NYX-458, an NMDAR modulator, in nonhuman primate models of Parkinson's disease.
• To assess NYX-458's effects on cognitive domains affected early in PD, including attention, working memory, and executive function.
• To investigate NYX-458's impact on motor symptoms and levodopa's therapeutic effects in PD models.

Main Methods:

• NYX-458 was tested in chronic low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD models.
• Cognitive functions were assessed using variable delayed response and simple discrimination reversal tasks.
• NYX-458 was also evaluated as monotherapy and with levodopa in high-dose MPTP models for motor effects.

Main Results:

• NYX-458 administration rapidly and sustainably improved attention, working memory, and executive function.
• Effective cognitive-enhancing doses of NYX-458 did not alter motor symptoms in PD models.
• NYX-458 did not affect the antiparkinsonian benefits of levodopa or cause dyskinesia.

Conclusions:

• NYX-458 effectively ameliorates cognitive deficits in a dopamine-depletion model of PD-like cognitive impairment.
• These findings support the continued investigation of NYX-458 as a therapeutic agent for cognitive decline in Parkinson's disease.
• NYX-458 demonstrates potential as a targeted treatment for specific cognitive impairments associated with PD.